ArticleFrontiers in pharmacology2018
Determining the Balance Between Drug Efficacy and Safety by the Network and Biological System Profile of Its Therapeutic Target.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes.Pharmaceutics · 2026Review
- Lifecycle regulation of narrow therapeutic index drugs: Chinese practices, international benchmarks, and optimization pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A pumpless liver-adipose model for studying metabolic dysfunction and drug responses.PloS one · 2026Article
- Artificial intelligence-assisted neuropharmacology: reshaping drug discovery and translational strategies for neurological diseases.Turkish journal of medical sciences · 2026Review
- The integration of machine learning into traditional Chinese medicine.Journal of pharmaceutical analysis · 2025Review
- Improved therapeutic approach for spinal muscular atrophy via ubiquitination-resistant survival motor neuron variant.Journal of cachexia, sarcopenia and muscle · 2024Article
- TTD: Therapeutic Target Database describing target druggability information.Nucleic acids research · 2024Article
- Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy.Biosensors · 2023Review
- Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs.Pharmaceutical research · 2023Article
- A network-biology led computational drug repurposing strategy to prioritize therapeutic options for COVID-19.Heliyon · 2022Article
- Evaluation of acute and sub-acute toxicity profile of 5-methylcoumarin-4β-glucoside in mice.Toxicology reports · 2022Article
- Bacteria-mediated cancer therapy: A versatile bio-sapper with translational potential.Frontiers in oncology · 2022Review
- Qing-Yi Decoction in the Treatment of Acute Pancreatitis: An Integrated Approach Based on Chemical Profile, Network Pharmacology, Molecular Docking and Experimental Evaluation.Frontiers in pharmacology · 2021Article
- Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease.Computational and structural biotechnology journal · 2021Article
- Electrochemical andJournal of pharmaceutical analysis · 2020Article
- Protein functional annotation of simultaneously improved stability, accuracy and false discovery rate achieved by a sequence-based deep learning.Briefings in bioinformatics · 2020Article
- Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.Briefings in bioinformatics · 2020Article
- Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics.Nucleic acids research · 2020Article
- Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables.Frontiers in pharmacology · 2020Review
- A methodology and theoretical taxonomy for centrality measures: What are the best centrality indicators for student networks?PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most challenging puzzles in drug discovery is the identification and characterization of candidate drug of well-balanced profile between efficacy and safety. So far, extensive efforts have been made to evaluate this balance by estimating the quantitative structure-therapeutic relationship and exploring target profile of adverse drug reaction. Particularly, the therapeutic index (TI) has emerged as a key indicator illustrating this delicate balance, and a clinically successful agent requires a sufficient TI suitable for it corresponding indication. However, the TI information are largely unknown for most drugs, and the mechanism underlying the drugs with narrow TI (NTI drugs) is still elusive. In this study, the collective effects of human protein-protein interaction (PPI) network and biological system profile on the drugs' efficacy-safety balance were systematically evaluated. First, a comprehensive literature review of the FDA approved drugs confirmed their NTI status. Second, a popular feature selection algorithm based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.